Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer.

Liu YL, Zhou Q, Iasonos A, Emengo VN, Friedman C, Konner JA, O'Cearbhaill RE, Aghajanian C, Zamarin D.

Gynecol Oncol. 2019 Oct;155(1):51-57. doi: 10.1016/j.ygyno.2019.08.006. Epub 2019 Aug 14.

PMID:
31421916
2.

Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status.

Stasenko M, Cybulska P, Feit N, Makker V, Konner J, O'Cearbhaill RE, Alektiar KM, Beal K, Gardner GJ, Long Roche KC, Sonoda Y, Chi DS, Zivanovic O, Leitao MM Jr, Cadoo KA, Tew WP.

Gynecol Oncol. 2019 Jul;154(1):144-149. doi: 10.1016/j.ygyno.2019.05.004. Epub 2019 May 18.

PMID:
31113680
3.

Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade.

Boland JL, Zhou Q, Martin M, Callahan MK, Konner J, O'Cearbhaill RE, Friedman CF, Tew W, Makker V, Grisham RN, Hensley ML, Zecca N, Iasonos AE, Snyder A, Hyman DM, Sabbatini P, Aghajanian C, Cadoo KA, Zamarin D.

Gynecol Oncol. 2019 Feb;152(2):251-258. doi: 10.1016/j.ygyno.2018.11.025. Epub 2018 Nov 22.

4.

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine.

Matulonis UA, Birrer MJ, O'Malley DM, Moore KN, Konner J, Gilbert L, Martin LP, Bauer TM, Oza AM, Malek K, Pinkas J, Kim SK.

Clin Cancer Res. 2019 Mar 15;25(6):1727-1736. doi: 10.1158/1078-0432.CCR-18-2474. Epub 2018 Nov 9.

PMID:
30413525
5.

Telemedical Coaching Improves Long-Term Weight Loss in Overweight Persons: A Randomized Controlled Trial.

Kempf K, Röhling M, Stichert M, Fischer G, Boschem E, Könner J, Martin S.

Int J Telemed Appl. 2018 Sep 9;2018:7530602. doi: 10.1155/2018/7530602. eCollection 2018.

6.

Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate.

Brand C, Sadique A, Houghton JL, Gangangari K, Ponte JF, Lewis JS, Pillarsetty NVK, Konner JA, Reiner T.

EJNMMI Res. 2018 Aug 28;8(1):87. doi: 10.1186/s13550-018-0437-x.

7.

A Feasibility Study of Restorative Yoga Versus Vigorous Yoga Intervention for Sedentary Breast and Ovarian Cancer Survivors.

Lapen K, Benusis L, Pearson S, Search B, Coleton M, Li QS, Sjoberg D, Konner J, Mao JJ, Deng G.

Int J Yoga Therap. 2018 Nov;28(1):79-85. doi: 10.17761/2018-00039. Epub 2018 Aug 17.

PMID:
30117760
8.

Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer.

Soumerai TE, Donoghue MTA, Bandlamudi C, Srinivasan P, Chang MT, Zamarin D, Cadoo KA, Grisham RN, O'Cearbhaill RE, Tew WP, Konner JA, Hensley ML, Makker V, Sabbatini P, Spriggs DR, Troso-Sandoval TA, Charen AS, Friedman C, Gorsky M, Schweber SJ, Middha S, Murali R, Chiang S, Park KJ, Soslow RA, Ladanyi M, Li BT, Mueller J, Weigelt B, Zehir A, Berger MF, Abu-Rustum NR, Aghajanian C, DeLair DF, Solit DB, Taylor BS, Hyman DM.

Clin Cancer Res. 2018 Dec 1;24(23):5939-5947. doi: 10.1158/1078-0432.CCR-18-0412. Epub 2018 Aug 1.

PMID:
30068706
9.

A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer.

LaVigne K, Hyman DM, Zhou QC, Iasonos A, Tew WP, Aghajanian C, Makker V, Hensley ML, Konner J, Grisham RN, Cangemi N, Soldan K, Spriggs DR, Sabbatini PJ, OʼCearbhaill RE.

Int J Gynecol Cancer. 2018 Jul;28(6):1176-1182. doi: 10.1097/IGC.0000000000001280.

10.

A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.

Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Vergote I, Ponte JF, Birrer MJ.

Future Oncol. 2018 Jan;14(2):123-136. doi: 10.2217/fon-2017-0379. Epub 2017 Nov 3. Review.

11.

Genetic predisposition to bevacizumab-induced hypertension.

Frey MK, Dao F, Olvera N, Konner JA, Dickler MN, Levine DA.

Gynecol Oncol. 2017 Dec;147(3):621-625. doi: 10.1016/j.ygyno.2017.09.017. Epub 2017 Sep 29.

PMID:
28969913
12.

Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.

Oseledchyk A, Leitao MM Jr, Konner J, O'Cearbhaill RE, Zamarin D, Sonoda Y, Gardner GJ, Long Roche K, Aghajanian CA, Grisham RN, Brown CL, Snyder A, Chi DS, Soslow RA, Abu-Rustum NR, Zivanovic O.

Ann Oncol. 2017 Dec 1;28(12):2985-2993. doi: 10.1093/annonc/mdx525.

13.

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.

Martin LP, Konner JA, Moore KN, Seward SM, Matulonis UA, Perez RP, Su Y, Berkenblit A, Ruiz-Soto R, Birrer MJ.

Gynecol Oncol. 2017 Nov;147(2):402-407. doi: 10.1016/j.ygyno.2017.08.015. Epub 2017 Aug 24.

14.

Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient.

Jiménez-Sánchez A, Memon D, Pourpe S, Veeraraghavan H, Li Y, Vargas HA, Gill MB, Park KJ, Zivanovic O, Konner J, Ricca J, Zamarin D, Walther T, Aghajanian C, Wolchok JD, Sala E, Merghoub T, Snyder A, Miller ML.

Cell. 2017 Aug 24;170(5):927-938.e20. doi: 10.1016/j.cell.2017.07.025.

15.

Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.

Weigelt B, Comino-Méndez I, de Bruijn I, Tian L, Meisel JL, García-Murillas I, Fribbens C, Cutts R, Martelotto LG, Ng CKY, Lim RS, Selenica P, Piscuoglio S, Aghajanian C, Norton L, Murali R, Hyman DM, Borsu L, Arcila ME, Konner J, Reis-Filho JS, Greenberg RA, Robson ME, Turner NC.

Clin Cancer Res. 2017 Nov 1;23(21):6708-6720. doi: 10.1158/1078-0432.CCR-17-0544. Epub 2017 Aug 1.

16.

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.

Soumerai JD, Zelenetz AD, Moskowitz CH, Palomba ML, Hamlin PA Jr, Noy A, Straus DJ, Moskowitz AJ, Younes A, Matasar MJ, Horwitz SM, Portlock CS, Konner JA, Gounder MM, Hyman DM, Voss MH, Fury MG, Gajria D, Carvajal RD, Ho AL, Beumer JH, Kiesel B, Zhang Z, Chen A, Little RF, Jarjies C, Dang TO, France F, Mishra N, Gerecitano JF.

Clin Cancer Res. 2017 Aug 1;23(15):4119-4126. doi: 10.1158/1078-0432.CCR-16-3068. Epub 2017 Mar 17.

17.

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.

Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ.

J Clin Oncol. 2017 Apr 1;35(10):1112-1118. doi: 10.1200/JCO.2016.69.9538. Epub 2016 Dec 28.

18.

Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.

Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, Nathanson KL, Konner JA, Arnold AG, Bogomolniy F, Dao F, Olvera N, Bancroft EK, Goldfrank DJ, Stadler ZK, Robson ME, Brown CL, Leitao MM Jr, Abu-Rustum NR, Aghajanian CA, Blum JL, Neuhausen SL, Garber JE, Daly MB, Isaacs C, Eeles RA, Ganz PA, Barakat RR, Offit K, Domchek SM, Rebbeck TR, Kauff ND.

JAMA Oncol. 2016 Nov 1;2(11):1434-1440. doi: 10.1001/jamaoncol.2016.1820.

19.

A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Bell-McGuinn KM, Konner JA, Tew WP, Hensley ML, Iasonos A, Charpentier E, Mironov S, Sabbatini P, Aghajanian C.

Int J Gynecol Cancer. 2016 Feb;26(2):255-60. doi: 10.1097/IGC.0000000000000591.

20.

Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.

Shu CA, Zhou Q, Jotwani AR, Iasonos A, Leitao MM Jr, Konner JA, Aghajanian CA.

Gynecol Oncol. 2015 Nov;139(2):236-41. doi: 10.1016/j.ygyno.2015.09.016. Epub 2015 Sep 25.

21.

Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.

Hyman DM, Snyder AE, Carvajal RD, Gerecitano JF, Voss MH, Ho AL, Konner J, Winkelmann JL, Stasi MA, Monson KR, Iasonos A, Spriggs DR, Bialer P, Lacouture ME, Teitcher JB, Katabi N, Fury MG.

Cancer Chemother Pharmacol. 2015 Apr;75(4):747-55. doi: 10.1007/s00280-015-2693-z. Epub 2015 Feb 12.

22.

Breaking down the evidence for bevacizumab in ovarian cancer.

Shu CA, Konner JA.

Oncologist. 2015 Feb;20(2):91-3. doi: 10.1634/theoncologist.2014-0302. Epub 2015 Jan 19. No abstract available.

23.

A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors.

Peethambaram PP, Hartmann LC, Jonker DJ, de Jonge M, Plummer ER, Martin L, Konner J, Marshall J, Goss GD, Teslenko V, Clemens PL, Cohen LJ, Ahlers CM, Alland L.

Invest New Drugs. 2015 Apr;33(2):321-31. doi: 10.1007/s10637-014-0171-9. Epub 2014 Nov 8.

PMID:
25380635
24.

Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies.

Andikyan V, Khoury-Collado F, Sandadi S, Tew WP, O'Cearbhaill RE, Konner JA, Sonoda Y, Barakat RR, Chi DS, Abu-Rustum NR.

Int J Gynecol Cancer. 2013 Jun;23(5):923-8. doi: 10.1097/IGC.0b013e318290ea8f.

PMID:
23698798
25.

Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.

Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, Jungbluth AA, Ritter G, Aghajanian C, Bell-McGuinn K, Hensley ML, Konner J, Tew W, Spriggs DR, Hoffman EW, Venhaus R, Pan L, Salazar AM, Diefenbach CM, Old LJ, Gnjatic S.

Clin Cancer Res. 2012 Dec 1;18(23):6497-508. doi: 10.1158/1078-0432.CCR-12-2189. Epub 2012 Oct 2.

26.

Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience.

Grisham RN, Adaniel C, Hyman DM, Ma W, Iasonos A, Aghajanian C, Konner J.

Int J Gynecol Cancer. 2012 Jun;22(5):807-11. doi: 10.1097/IGC.0b013e31824a33a2.

27.

Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.

Barlin JN, Dao F, Bou Zgheib N, Ferguson SE, Sabbatini PJ, Hensley ML, Bell-McGuinn KM, Konner J, Tew WP, Aghajanian C, Chi DS.

Gynecol Oncol. 2012 Jun;125(3):621-4. doi: 10.1016/j.ygyno.2012.03.027. Epub 2012 Mar 21.

PMID:
22446622
28.

Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors.

Balagula Y, Rosen A, Tan BH, Busam KJ, Pulitzer MP, Motzer RJ, Feldman DR, Konner JA, Reidy-Lagunes D, Myskowski PL, Lacouture ME.

Cancer. 2012 Oct 15;118(20):5078-83. doi: 10.1002/cncr.27505. Epub 2012 Mar 21.

29.

New drugs for ovarian cancer.

Bell-McGuinn K, Konner J, Tew W, Spriggs DR.

Ann Oncol. 2011 Dec;22 Suppl 8:viii77-viii82. doi: 10.1093/annonc/mdr531. Review. No abstract available.

PMID:
22180408
30.

Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma.

Konner J, Grisham RN, Park J, O'Connor OA, Cropp G, Johnson R, Hannah AL, Hensley ML, Sabbatini P, Mironov S, Danishefsky S, Hyman D, Spriggs DR, Dupont J, Aghajanian C.

Invest New Drugs. 2012 Dec;30(6):2294-302. doi: 10.1007/s10637-011-9765-7. Epub 2011 Nov 10. Erratum in: Invest New Drugs. 2012 Dec;30(6):2450. Miranov, Svetlana [corrected to Mironov, Svetlana].

31.

Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.

Konner JA, Grabon DM, Gerst SR, Iasonos A, Thaler H, Pezzulli SD, Sabbatini PJ, Bell-McGuinn KM, Tew WP, Hensley ML, Spriggs DR, Aghajanian CA.

J Clin Oncol. 2011 Dec 10;29(35):4662-8. doi: 10.1200/JCO.2011.36.1352. Epub 2011 Nov 7.

32.

Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer.

Tanner EJ, Black DR, Zivanovic O, Kehoe SM, Dao F, Konner JA, Barakat RR, Lichtman SM, Levine DA.

Gynecol Oncol. 2012 Jan;124(1):59-62. doi: 10.1016/j.ygyno.2011.09.011. Epub 2011 Oct 7.

PMID:
21982046
33.

Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity.

Gallagher DJ, Konner JA, Bell-McGuinn KM, Bhatia J, Sabbatini P, Aghajanian CA, Offit K, Barakat RR, Spriggs DR, Kauff ND.

Ann Oncol. 2011 May;22(5):1127-32. doi: 10.1093/annonc/mdq577. Epub 2010 Nov 17.

34.

Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study.

Konner JA, Bell-McGuinn KM, Sabbatini P, Hensley ML, Tew WP, Pandit-Taskar N, Vander Els N, Phillips MD, Schweizer C, Weil SC, Larson SM, Old LJ.

Clin Cancer Res. 2010 Nov 1;16(21):5288-95. doi: 10.1158/1078-0432.CCR-10-0700. Epub 2010 Sep 20.

35.

Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma.

Diaz JP, Tew WP, Zivanovic O, Konner J, Sabbatini PJ, dos Santos LA, Abu-Rustum NR, Chi DS, Aghajanian C, Barakat RR.

Gynecol Oncol. 2010 Mar;116(3):335-9. doi: 10.1016/j.ygyno.2009.11.017. Epub 2009 Dec 11.

PMID:
20004956
36.

Consolidation strategies in ovarian cancer: observations for future clinical trials.

Sabbatini P, Spriggs D, Aghajanian C, Hensley M, Tew W, Konner J, Bell-McGuinn K, Juretzka M, Iasonos A.

Gynecol Oncol. 2010 Jan;116(1):66-71. doi: 10.1016/j.ygyno.2009.09.016.

37.

A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer.

Chi DS, Phaëton R, Miner TJ, Kardos SV, Diaz JP, Leitao MM Jr, Gardner G, Huh J, Tew WP, Konner JA, Sonoda Y, Abu-Rustum NR, Barakat RR, Jaques DP.

Oncologist. 2009 Aug;14(8):835-9. doi: 10.1634/theoncologist.2009-0057. Epub 2009 Aug 14.

38.

Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study.

Hensley ML, Ishill N, Soslow R, Larkin J, Abu-Rustum N, Sabbatini P, Konner J, Tew W, Spriggs D, Aghajanian CA.

Gynecol Oncol. 2009 Mar;112(3):563-7. doi: 10.1016/j.ygyno.2008.11.027. Epub 2009 Jan 9.

PMID:
19135708
39.

A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission.

Juretzka M, Hensley ML, Tew W, Konner J, Aghajanian C, Leitao M, Iasonos A, Soslow R, Park K, Sabbatini P.

Eur J Gynaecol Oncol. 2008;29(6):568-72.

PMID:
19115680
40.

Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy.

Zivanovic O, Leitao MM Jr, Park KJ, Zhao H, Diaz JP, Konner J, Alektiar K, Chi DS, Abu-Rustum NR, Aghajanian C.

Gynecol Oncol. 2009 Mar;112(3):590-3. doi: 10.1016/j.ygyno.2008.11.010. Epub 2008 Dec 24.

PMID:
19110302
41.

A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer.

Hensley ML, Larkin J, Fury M, Gerst S, Tai DF, Sabbatini P, Konner J, Orlando M, Goss TL, Aghajanian CA.

Clin Cancer Res. 2008 Oct 1;14(19):6310-6. doi: 10.1158/1078-0432.CCR-08-0338.

42.

A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.

Konner J, Schilder RJ, DeRosa FA, Gerst SR, Tew WP, Sabbatini PJ, Hensley ML, Spriggs DR, Aghajanian CA.

Gynecol Oncol. 2008 Aug;110(2):140-5. doi: 10.1016/j.ygyno.2008.04.018. Epub 2008 Jun 13.

PMID:
18554700
43.

Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: results of long-term follow-up.

Zivanovic O, Barakat RR, Sabbatini PJ, Brown CL, Konner JA, Aghajanian CA, Abu-Rustum NR, Levine DA.

Cancer. 2008 Jun 15;112(12):2690-7. doi: 10.1002/cncr.23485.

44.

Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.

Smith-Jones PM, Pandit-Taskar N, Cao W, O'Donoghue J, Philips MD, Carrasquillo J, Konner JA, Old LJ, Larson SM.

Nucl Med Biol. 2008 Apr;35(3):343-51. doi: 10.1016/j.nucmedbio.2007.12.008.

45.

A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission.

Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C, Lewin S, Konner J, Derosa F, Spriggs D, Iasonos A, Sabbatini P.

Cancer. 2007 Dec 1;110(11):2448-56.

46.

Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.

Sabbatini PJ, Ragupathi G, Hood C, Aghajanian CA, Juretzka M, Iasonos A, Hensley ML, Spassova MK, Ouerfelli O, Spriggs DR, Tew WP, Konner J, Clausen H, Abu Rustum N, Dansihefsky SJ, Livingston PO.

Clin Cancer Res. 2007 Jul 15;13(14):4170-7.

47.

Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy.

Sabbatini P, Mooney D, Iasonos A, Thaler H, Aghajanian C, Hensley M, Konner J, Spriggs D, Abu-Rustum NR, Dupont J.

Int J Gynecol Cancer. 2007 May-Jun;17(3):589-94. Epub 2007 Feb 9.

PMID:
17300679
48.

Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study.

Sovak MA, Dupont J, Hensley ML, Ishill N, Gerst S, Abu-Rustum N, Anderson S, Barakat R, Konner J, Poyner E, Sabbatini P, Spriggs DR, Aghajanian C.

Int J Gynecol Cancer. 2007 Jan-Feb;17(1):197-203.

PMID:
17291253
49.

Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.

Diefenbach CS, Shah Z, Iasonos A, Barakat RR, Levine DA, Aghajanian C, Sabbatini P, Hensley ML, Konner J, Tew W, Spriggs D, Fleisher M, Thaler H, Dupont J.

Gynecol Oncol. 2007 Feb;104(2):435-42. Epub 2006 Oct 4.

PMID:
17023034
50.

Supplemental Content

Loading ...
Support Center